Research article · 9 Aug 2017
Conference abstractPublished 17 Sep 2018
Fujifilms microneedle array technology
Fujifilm Corporation, Japan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Fujifilm has been developing microneedle array (MNA) of dissolvable type, from 2011. Followings 2 topics were investigated and published. For future aseptic mass production, Fujifilm owns the facility for manufacturing investigational new drug (capable for aseptic production) and developing mass production technologies. In this presentation, results of animal experiments are mainly reported. 1st topic: MNA incorporating influenza vaccine Ether-split and whole virus particles inactivated with formalin were prepared from two type of influenza virus, A/Puerto Rico/8/1934 (H1N1) (PR8) and A/duck/Hokkaido/Vac-3 (H5N1) (Vac-3). These vaccines were incorporated in MNA. BALB/c mice were vaccinated by MNA or subcutaneous injection. MNA containing ether-split or whole virus particle of PR8 shown higher neutralizing antibodies than subcutaneous injection. MNA containing PR8 of whole virus particle shown immunogenicity at lower vaccine dose, compared to MNA containing PR8 of ether split. Furthermore, survival rates of MNA vaccinated mice were significantly higher than subcutaneously vaccinated mice. Virus titer in lung correlated with neutralizing antibody titer in serum. Similar results were obtained with Vac-3. 2nd topic: MNA incorporating hepatitis B surface antigen (HBsAg) HBsAg was incorporated into MNA with or without adjuvant (saponin QS-21). Yorkshire/Landrace F1 (Y x L) x Duroc swine were vaccinated by MNA or intramuscular injection. Commercial HBsAg vaccine containing Al(OH)3 as adjuvant (Engerix-B) was used as a reference. Non-adjuvanted MNA boost after priming with Engerix-B was non-inferior to the benchmark (twice Engerix-B). MNA worked as booster vaccine, without the use of an adjuvant. However, single MNA priming did not elicit an anti-HBsAg antibody response. For QS-21 adjuvanted MNA, twice MNA administration was non-inferior to the benchmark (twice Engerix-B). Also, single MNA priming was able to elicit an anti-HBsAg antibody response.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2017
Hydrogel-forming microneedle arrays: Potential for use in minimally-invasive lithium monitoring
Mini review · 29 Aug 2024
Microneedle Technologies in Transdermal Drug Delivery: Improving Bioavailability and Patient Compliance
Perspective · 6 Apr 2023
Challenges in using Microneedle Technology for the Treatment of Warts
Conference abstract · 2019
Microneedle vaccine technology
More from this journal
The newest in Journal of Pharmaceutical Care & Health Systems.
Review article · 9 Jun 2025
Blood Fluid: The Unseen Currents That Bind Life and Death Together
Research article · 8 Jun 2025
Formulation and Antibacterial Evaluation of Acmella olaracea (Akarkara) Gummies Used for Toothache
Research article · 9 Apr 2025
Deep Vein Thrombosis: A Closer Look at a Silent Threat
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Care & Health Systems
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Hisahiro Mori”

